United States Securities And Exchange Commission
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 18, 2009 (November 13, 2009) | ||
ISORAY, INC. (Exact name of registrant as specified in its charter) | ||
Minnesota (State or other jurisdiction of incorporation) | 001-33407 (Commission File Number) | 41-1458152 (IRS Employer Identification No.) |
350 Hills Street, Suite 106, Richland, Washington 99354
(Address of principal executive offices) (Zip Code)
(509) 375-1202
(Registrant's telephone number)
ITEM 1.01 Entry into a Material Definitive Agreement
On November 13, 2009, IsoRay Medical, Inc. ("Medical"), a wholly owned subsidiary of IsoRay, Inc. (the "Registrant"), entered into a Distributor Agreement (the "Agreement") with Inter V Medical, Inc., a Canadian company ("Inter V"), with the Agreement having an effective date of November 10, 2009. Under the Agreement, Inter V will be the exclusive distributor of Medical's Cesium-131 products in Canada, subject to loss of exclusivity if Inter V fails to meet certain of its obligations under the Agreement. The Agreement will expire on November 10, 2011 unless earlier terminated or renewed by the parties.
ITEM 9.01 Exhibits
| (c) | Exhibits |
| 10.54 | Distributor Agreement, dated effective November 10, 2009, by and between IsoRay Medical, Inc. and Inter V Medical, Inc. (confidential treatment requested for redacted portions) |
SIGNATURES
In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: November 17, 2009
| IsoRay, Inc., a Minnesota corporation | |||
| By: | /s/ Dwight Babcock | ||
| Dwight Babcock, CEO | |||